SYNCROSOME, part of the ETAP-LAB group, has been selected to participate in the EU-Japan Biotech Business Mission 2026, a business delegation organized by the EU-Japan Centre for Industrial Cooperation to foster collaborations between European and Japanese stakeholders in the biotechnology, pharmaceutical, and healthcare sectors.
Three Key Events at the Heart of Asian Biotech Innovation
From October 5 to 9, 2026, Nicolas Violle, CEO of SYNCROSOME, will represent the company at several leading industry events and business meetings bringing together pharmaceutical and biotechnology companies, research centers, and innovation stakeholders from Asia, Europe, and around the world.
Osaka, October 5, 2026 | EU-Japan Biotech & Pharma Partnering Conference 2026
The first stop of the mission, this partnering conference in Osaka is dedicated to B2B meetings between European and Japanese pharmaceutical and biotechnology companies. Participants can schedule pre-arranged meetings to identify scientific, technological, and commercial collaboration opportunities.
→ Learn more: EU-Japan Biotech & Pharma Partnering Conference 2026
Osaka, October 6, 2026 | Global Startup Expo 2026
Following the partnering conference, SYNCROSOME will also participate in the Global Startup Expo 2026, with a dedicated business meeting program aimed at continuing discussions initiated in Osaka and engaging with new potential partners across the Asian market.
→ Learn more: Global Startup Expo 2026
Yokohama, October 7-9, 2026 | BioJapan 2026
The mission will continue in Yokohama with participation in BioJapan 2026, widely recognized as one of Asia’s premier biotech partnering events. The 2025 edition welcomed more than 22,000 visitors, over 1,100 exhibiting organizations, and facilitated more than 25,000 partnering meetings. Based at the European collective pavilion B-06 with its own dedicated booth, Nicolas Violle will meet pharmaceutical laboratories and biotechnology companies seeking preclinical partners for their drug development programs.
→ Learn more: BioJapan 2026
Spotlight on ETAP-LAB’s Preclinical Expertise Presented During Business Meetings
Through SYNCROSOME, ETAP-LAB will showcase its full range of in vitro and in vivo preclinical pharmacology expertise:
- Cardiology through SYNCROSOME;
- Dermatology through SKINAXIS;
- Neurology through BRAINXPLORE;
- Stroke and Neurovascular Disorders through STROK@LLIANCE.
The objective is to introduce new Asian partners to the group’s capabilities in supporting pharmaceutical and biotechnology research and development programs, from early exploratory phases through advanced preclinical stages. Interest in ETAP-LAB’s participation is already evident through a particularly busy partnering schedule, with numerous meetings already confirmed.
Innovation Capabilities Recognized at the European Level
SYNCROSOME’s participation in this mission follows a selection process conducted by the EU-Japan Centre for Industrial Cooperation. The mission is reserved for a limited number of innovative European companies seeking to expand their presence in Japan and establish partnerships within the local life sciences ecosystem. Up to 16 participants may be selected for the 2026 edition. For ETAP-LAB, this selection recognizes the scientific expertise and innovation capabilities developed by its teams, while also providing a concrete opportunity to accelerate growth with new pharmaceutical and biotechnology clients across Asia.
As part of the international development support available to innovative life sciences companies, we benefit from the support of:
- the South Provence-Alpes-Côte d’Azur Region;
- Eurobiomed, the health innovation competitiveness cluster of Southern France;
- EU-Japan Centre for Industrial Cooperation;
- Rising Sud, in close collaboration with the Enterprise Europe Network (EEN).
An Opportunity to Accelerate Our Presence in the Japanese Market
This participation marks a new milestone in our international development. While ETAP-LAB already collaborates with several Japanese organizations, this mission represents the company’s first participation in major professional events in Japan. Our objective is clear: strengthen our visibility in this strategic market, build new collaborations, and support an increasing number of pharmaceutical and biotechnology companies in their preclinical research programs.
